We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- Medivation, Inc. (NASDAQ:MDVN) today announced that its common stock will begin trading on The Nasdaq Global Market under the symbol MDVN at the...
SAN FRANCISCO, March 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy...
Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV) reiterating a Strong Speculative Buy rating and a $27.00 price target. The 12-page report by Dutton senior...
SAN FRANCISCO, March 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that The Nasdaq Listing Qualifications Department has approved the Company's application to list its...
SAN FRANCISCO, March 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at Cowen and Company's...
- Data Presented in Oral and Poster Presentations at ASCO's Prostate Cancer Symposium - SAN FRANCISCO, Feb. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results...
SAN FRANCISCO, Feb. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that preclinical efficacy data on MDV3100, a novel small molecule the Company is developing to treat...
SAN FRANCISCO, Feb. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at the 9th Annual BIO CEO...
SAN FRANCISCO, Jan. 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results of its Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented at...
SAN FRANCISCO, Jan. 17 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) today announced that it has appointed Lisa Taylor as vice president of commercial development. Ms. Taylor is responsible for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Symbol | Price | Vol. |
---|---|---|
MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 0.9467 (-11.52%) | 795.18M |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3.22 (6.62%) | 56.33M |
FXIiShares China Large Cap | US$ 29.69 (-2.17%) | 53.99M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 28.49 (0.00%) | 50.44M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 6.035 (-0.74%) | 49.69M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions